B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

RAC-ALPHA

MOLECULAR TARGET

RAC-alpha serine/threonine-protein kinase (human)

UniProt: P3174914 compounds

RAC-ALPHA (RAC-alpha serine/threonine-protein kinase (human)) is targeted by 14 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting RAC-ALPHA

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Gemcitabine1.614
2Resveratrol1.393
3pictilisib1.393
4Perphenazine1.102
5withaferin1.102
6plumbagin [Supplementary Concept]0.691
7Quercetin0.691
8Sirolimus0.691
9chicoric acid0.691
10Dasatinib0.691
11hydroxyfasudil [Supplementary Concept]0.691
12Lovastatin0.691
13ly2940020.691
14Topotecan0.691

About RAC-ALPHA as a Drug Target

RAC-ALPHA (RAC-alpha serine/threonine-protein kinase (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 14 compounds with documented RAC-ALPHA interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

RAC-ALPHA inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.